Lack of association between the functional polymorphisms in the estrogen-metabolizing genes and risk for hepatocellular carcinoma

Cancer Epidemiology Biomarkers and Prevention

Volumn 17, Issue 12, 2008, Pages 3621-3627

  Yuan, Xiaoyan ^a,b   Zhou, Gangqiao ^a,b   Zhai, Yun ^a,b   Xie, Weimin ^c   Cui, Ying ^c   Cao, Jia ^a,b   Zhi, Lianteng ^a,b   Zhang, Hongxing ^a,b   Yang, Hao ^a,b   Zhang, Xiaoai ^a,b   Qiu, Wei ^a,b   Peng, Yong ^c   Zhang, Xiumei ^a,b   Yu, Ling ^a,b   Xia, Xia ^a,b   He, Fuchu ^a,b,d  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b THIRD MILITARY MEDICAL UNIVERSITY   (China)

^c Guangxi Cancer Institute   (China)

^d FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

AROMATASE; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 17; CYTOCHROME P450 1A1; CYTOCHROME P450 1B1;

ARTICLE; CANCER DIAGNOSIS; CANCER RISK; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME DEGRADATION; FEMALE; GENE FREQUENCY; GENE INTERACTION; GENETIC ASSOCIATION; HAPLOTYPE; HEPATITIS B VIRUS; HUMAN; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM;

AROMATASE; ARYL HYDROCARBON HYDROXYLASES; CARCINOMA, HEPATOCELLULAR; CASE-CONTROL STUDIES; CATECHOL O-METHYLTRANSFERASE; CYTOCHROME P-450 CYP1A1; ESTROGENS; FEMALE; GENOTYPE; HAPLOTYPES; HUMANS; LIVER NEOPLASMS; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; POLYMORPHISM, RESTRICTION FRAGMENT LENGTH; RISK; STEROID 17-ALPHA-HYDROXYLASE;

EID: 57449083233     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-08-0742     Document Type: Article

References (31)

1. Nelson R. Steroidal oestrogens added to list of known human carcinogens. Lancet 2002;360:2053.
2. Coe JE, Ishak KG, Ross MJ. Estrogen induction of hepatocellular carcinomas in Armenian hamsters. Hepatology 1990;11:570-7.
3. Neuberger J, Forman D, Doll R, Williams R. Oral contraceptives and hepatocellular carcinoma. Br Med J 1986;292:1355-7.
4. Yu MC, Yuan JM. Environmental factors and risk for hepatocellular carcinoma. Gastroenterology 2004;127:S72-8.
5. Zhai Y, Zhou G, Deng G, et al. Estrogen receptor α polymorphisms associated with susceptibility to hepatocellular carcinoma in hepatitis B virus carriers. Gastroenterology 2006;130:2001-9.
6. Cavalieri E, Frenkel K, Liehr JG, Rogan E, Roy D. Estrogens as endogenous genotoxic agents - DNA adducts and mutations. J Natl Cancer Inst Monogr 2000;27:75-93.
7. Newbold RR, Hanson RB, Jefferson WN, Bullock BC, Haseman J, McLachlan JA. Proliferative lesions and reproductive tract tumors in male descendants of mice exposed developmentally to diethylstilbestrol. Carcinogenesis 2000;21:1355-63.
8. Lavigne JA, Helzlsouer KJ, Huang HY, et al. An association between the allele coding for a low activity variant of catechol-O-methyltransferase and the risk for breast cancer. Cancer Res 1997;57:5493-7.
9. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Genet 1994;3:1873-6.
10. Feigelson HS, Shames LS, Pike MC, Coetzee GA, Stanczyk FZ, Henderson BE. Cytochrome P450c17alpha gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res 1998;58:585-7.
11. Nativelle-Serpentini C, Lambard S, Séralini GE, Sourdaine P. Aromatase and breast cancer: W39R, an inactive protein. Eur J Endocrinol 2002;146:583-9.
12. Crofts F, Taioli E, Trachman J, et al. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994;15:2961-3.
13. Kisselev P, Schunck WH, Roots I, Schwarz D. Association of CYP1A1 polymorphisms with differential metabolic activation of 17beta-estradiol and estrone. Cancer Res 2005;65:2972-8.
14. Li DN, Seidel A, Pritchard MP, Wolf CR, Friedberg T. Polymorphisms in P450 CYP1B1 affect the conversion of estradiol to the potentially carcinogenic metabolite 4-hydroxyestradiol. Pharmacogenetics 2000;10:343-53.
15. Lachman HM, Papolos DF, Saito T, Yu YM, Szumlanski CL, Weinshilboum RM. Human catechol-O-methyltransferase pharmacogenetics: description of a functional polymorphism and its potential application to neuropsychiatric disorders. Pharmacogenetics 1996;6:243-50.
16. Lee SG, Joo Y, Kim B, et al. Association of Ala72Ser polymorphism with COMT enzyme activity and the risk of schizophrenia in Koreans. Hum Genet 2005;116:319-28.
17. Shen Y, Li DK, Wu J, Zhang Z, Gao E. Joint effects of the CYP1A1 MspI, ERalpha PvuII, and ERalpha XbaI polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol Biomarkers Prev 2006;15:342-7.
18. Zhang L, Gu L, Qian B, et al. Association of genetic polymorphisms of ER-alpha and the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in Chinese women. Breast Cancer Res Treat. Epub 2008 Jul 16.
19. Sasaki M, Tanaka Y, Kaneuchi M, Sakuragi N, Dahiya R. CYP1B1 gene polymorphisms have higher risk for endometrial cancer, and positive correlations with estrogen receptor alpha and estrogen receptor beta expressions. Cancer Res 2003;63:3913-8.
20. Garner EI, Stokes EE, Berkowitz RS, Mok SC, Cramer DW. Polymorphisms of the estrogen-metabolizing genes CYP17 and catechol -O-methyltransferase and risk of epithelial ovarian cancer. Cancer Res 2002;62:3058-62.
21. Tanaka Y, Sasaki M, Shiina H, et al. Catechol-O-methyltransferase gene polymorphisms in benign prostatic hyperplasia and sporadic prostate cancer. Cancer Epidemiol Biomarkers Prev 2006;15:238-44.
22. Zhai Y, Qiu W, Dong XJ, et al. Functional polymorphisms in the promoters of MMP-1, MMP-2, MMP-3, MMP-9, MMP-12 and MMP-13 are not associated with hepatocellular carcinoma risk. Gut 2007;56:445-7.
23. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics 2003;19:376-82.
24. Chen CJ, Yu MW, Liaw YF. Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;12:S294-308.
25. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 2005;19:3-23.
26. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007;132:2557-76.
27. Huang CS, Chern HD, Chang KJ, Cheng CW, Hsu SM, Shen CY. Breast cancer risk associated with genotype polymorphism of the estrogen-metabolizing genes CYP17, CYP1A1, and COMT: a multigenic study on cancer susceptibility. Cancer Res 1999;59:4870-5.
28. Yin PH, Lee HC, Chau GY, et al. Polymorphisms of estrogen-metabolizing genes and risk of hepatocellular carcinoma in Taiwan females. Cancer Lett 2004;212:195-201.
29. Yu MW, Chiu YH, Yang SY, et al. Cytochrome P450 1A1 genetic polymorphisms and risk of hepatocellular carcinoma among chronic hepatitis B carriers. Br J Cancer 1999;80:598-603.
30. Silvestri L, Sonzogni L, De Silvestri A, et al. CYP enzyme polymorphisms and susceptibility to HCV-related chronic liver disease and liver cancer. Int J Cancer 2003;104:310-7.
31. Rossi L, Leveri M, Gritti C, et al. Genetic polymorphisms of steroid hormone metabolizing enzymes and risk of liver cancer in hepatitis C- infected patients. J Hepatol 2003;39:564-70.